Wedbush reiterates Outperform rating on Damora Therapeutics, $40 price target
Wedbush reiterated their Outperform rating on Damora Therapeutics's stock with a price target of $40.00.The price target implies an upside of 92.8% from the Sep 28 close of $20.75.Key takeaways from the analyst noteStrong Clinical Differentiation: Damora Therapeutics's DMR-001 is positioned to offe…